S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
This Stock Could Go Up 66% or More. (Ad)
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
How major US stock indexes fared Friday, 9/29/2023
This Stock Could Go Up 66% or More. (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
This Stock Could Go Up 66% or More. (Ad)
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
How major US stock indexes fared Friday, 9/29/2023
This Stock Could Go Up 66% or More. (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
This Stock Could Go Up 66% or More. (Ad)
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
How major US stock indexes fared Friday, 9/29/2023
This Stock Could Go Up 66% or More. (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
This Stock Could Go Up 66% or More. (Ad)
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
How major US stock indexes fared Friday, 9/29/2023
This Stock Could Go Up 66% or More. (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
NYSE:BLCO

Bausch + Lomb (BLCO) Stock Forecast, Price & News

$16.95
+0.15 (+0.89%)
(As of 09/29/2023 ET)
Compare
Today's Range
$16.80
$17.14
50-Day Range
$16.80
$19.90
52-Week Range
$12.79
$21.95
Volume
548,747 shs
Average Volume
408,324 shs
Market Capitalization
$5.94 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.50

Bausch + Lomb MarketRank™ Forecast

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
20.9% Upside
$20.50 Price Target
Short Interest
Healthy
11.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.97mentions of Bausch + Lomb in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
54.29%
From $0.70 to $1.08 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

429th out of 969 stocks

Ophthalmic Goods Industry

5th out of 7 stocks


BLCO stock logo

About Bausch + Lomb (NYSE:BLCO) Stock

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products for therapeutic use, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, dry eye, and redness relief. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

BLCO Price History

BLCO Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Bausch + Lomb Launches MIEBO To Treat Dry Eye Disease
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Bausch + Lomb (NYSE: BLCO)
See More Headlines
Receive BLCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter.

BLCO Company Calendar

Last Earnings
8/02/2023
Today
9/30/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Ophthalmic goods
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
12,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.50
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+20.9%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
8 Analysts

Profitability

Net Income
$6 million
Pretax Margin
-1.46%

Debt

Sales & Book Value

Annual Sales
$3.77 billion
Cash Flow
$2.20 per share
Book Value
$20.29 per share

Miscellaneous

Free Float
N/A
Market Cap
$5.95 billion
Optionable
Not Optionable
Beta
0.22
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Osama A. Eldessouky (Age 51)
    Exec. VP & CFO
    Comp: $1.09M
  • Dr. Yehia Hashad M.D. (Age 56)
    Exec. VP of R&D and Chief Medical officer
    Comp: $1.09M
  • Mr. Brenton L. Saunders J.D. (Age 53)
    CEO & Chairman
  • Mr. Alan Waterhouse CPFA (Age 63)
    MBA, Exec. VP and Chief Supply Chain & Operations Officer
  • Mr. Frederick J. Munsch (Age 53)
    Sr. VP, Controller & Chief Accounting Officer
  • Mr. A. Robert D. Bailey (Age 60)
    Exec. VP & Chief Legal Officer
  • Mr. Jonathon L. Kellerman
    Chief Compliance Officer
  • T.J. Crawford
    Chief Communications Officer
  • Dr. Manisha A. Narasimhan Ph.D. (Age 46)
    Chief Corp. Devel. & Digital Officer
  • Ms. Asli Gevgilili
    Exec. VP & Chief HR Officer













BLCO Stock - Frequently Asked Questions

Should I buy or sell Bausch + Lomb stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch + Lomb in the last twelve months. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BLCO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLCO, but not buy additional shares or sell existing shares.
View BLCO analyst ratings
or view top-rated stocks.

What is Bausch + Lomb's stock price forecast for 2023?

8 brokerages have issued 12 month price objectives for Bausch + Lomb's shares. Their BLCO share price forecasts range from $17.00 to $25.00. On average, they predict the company's share price to reach $20.50 in the next twelve months. This suggests a possible upside of 20.9% from the stock's current price.
View analysts price targets for BLCO
or view top-rated stocks among Wall Street analysts.

How have BLCO shares performed in 2023?

Bausch + Lomb's stock was trading at $15.51 at the start of the year. Since then, BLCO stock has increased by 9.3% and is now trading at $16.96.
View the best growth stocks for 2023 here
.

Are investors shorting Bausch + Lomb?

Bausch + Lomb saw a drop in short interest in September. As of September 15th, there was short interest totaling 4,270,000 shares, a drop of 14.3% from the August 31st total of 4,980,000 shares. Based on an average daily volume of 482,700 shares, the short-interest ratio is presently 8.8 days. Currently, 11.2% of the shares of the company are sold short.
View Bausch + Lomb's Short Interest
.

When is Bausch + Lomb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our BLCO earnings forecast
.

How were Bausch + Lomb's earnings last quarter?

Bausch + Lomb Co. (NYSE:BLCO) released its quarterly earnings data on Wednesday, August, 2nd. The company reported $0.18 EPS for the quarter, topping analysts' consensus estimates of $0.16 by $0.02. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $963.69 million. Bausch + Lomb had a positive trailing twelve-month return on equity of 4.09% and a negative net margin of 3.61%. Bausch + Lomb's revenue for the quarter was up 10.0% on a year-over-year basis. During the same period last year, the business earned $0.29 EPS.

What ETFs hold Bausch + Lomb's stock?

ETFs with the largest weight of Bausch + Lomb (NYSE:BLCO) stock in their portfolio include Ballast Small/Mid Cap ETF (MGMT).First Trust US Equity Opportunities ETF (FPX).

What guidance has Bausch + Lomb issued on next quarter's earnings?

Bausch + Lomb updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.95 billion-$4.00 billion, compared to the consensus revenue estimate of $5.20 billion.

When did Bausch + Lomb IPO?

(BLCO) raised $788 million in an initial public offering on Friday, May 6th 2022. The company issued 35,000,000 shares at $21.00-$24.00 per share.

What is Bausch + Lomb's stock symbol?

Bausch + Lomb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BLCO."

How do I buy shares of Bausch + Lomb?

Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bausch + Lomb's stock price today?

One share of BLCO stock can currently be purchased for approximately $16.96.

How much money does Bausch + Lomb make?

Bausch + Lomb (NYSE:BLCO) has a market capitalization of $5.95 billion and generates $3.77 billion in revenue each year. The company earns $6 million in net income (profit) each year or ($0.40) on an earnings per share basis.

How many employees does Bausch + Lomb have?

The company employs 12,900 workers across the globe.

How can I contact Bausch + Lomb?

The official website for the company is www.bausch.com. The company can be reached via phone at 905-695-7700.

This page (NYSE:BLCO) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -